newsfilter
← Latest News
Business Wire·

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

Pivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) continues to be projected to reach final survival event trigger within first